MedEfficiency
Stage
Acquired | AcquiredValuation
$0000Revenue
$0000About MedEfficiency
MedEfficiency is a medical products company that is focused on the development, manufacturing, and marketing of medical devices for treating chronic wounds and lower extremity injuries. MedEfficiency specializes in total contact casting (TCC) products for off-loading diabetic foot ulcers. The company has developed new products using advanced technology to change the ways these conditions are treated and result in improved clinical outcomes and cost effective treatments. TCC-EZ is the next generation of Total Contact Casting. TCC-EZ was developed to provide equivalent off-loading to a traditional total contact cast; yet it is much faster and easier to apply than a traditional TCC. In April 2012, MedEfficiency was acquired by Derma Sciences. The valuation of MedEfficiency was $14.5 million Other terms of the deal were not released.
Missing: MedEfficiency's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: MedEfficiency's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing MedEfficiency
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
MedEfficiency is included in 1 Expert Collection, including Diabetes.
Diabetes
1,904 items
MedEfficiency Patents
MedEfficiency has filed 7 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/16/2017 | 4/14/2020 | Rare diseases, Diabetes, Neurological disorders, Bone fractures, Syndromes | Grant |
Application Date | 3/16/2017 |
|---|---|
Grant Date | 4/14/2020 |
Title | |
Related Topics | Rare diseases, Diabetes, Neurological disorders, Bone fractures, Syndromes |
Status | Grant |
Latest MedEfficiency News
Apr 20, 2012
The European Commission clears Johnson & Johnson's $21.3 billion buyout of orthopedics giant Synthes after J&J agrees to ditch its DePuy trauma operation to Biomet; also, Intuitive Surgical CEO Guthart practices the Buffett rule; Biolase exits Henry Schein deal; SeraCare shareholders OK $81M Linden Capital buyout; Visium boosts stake in Syneron; Derma Sciences closes MedEfficiency buyout; plus, a Funding Roundup and analysts' ups and downs. Johnson & Johnson's (NYSE:JNJ) move to ditch its DePuy trauma business mollified EuroZone anti-trust regulators enough to win their approval for its $21.3 billion buyout of Synthes Inc. News Well, Mergers & Acquisitions, Orthopedics, Wall Street Beatread more
MedEfficiency Frequently Asked Questions (FAQ)
Where is MedEfficiency's headquarters?
MedEfficiency's headquarters is located at 5161 Ward Road, Wheat Ridge.
What is MedEfficiency's latest funding round?
MedEfficiency's latest funding round is Acquired.
Who are the investors of MedEfficiency?
Investors of MedEfficiency include Derma Sciences.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.